Product Options. Where specification paragraphs or subparagraphs titled “Product Options” indicate that size, profiles, and dimensional requirements on drawings are based on a specific product or system, provide either the specific product or system indicated, or a comparable product or system by one of the other named manufacturers. As stated in Subparagraph 4.c above, products must be approved by the substitution process set forth in Section 13.06 below in order to be deemed “comparable.”
Product Options. 4.1.1 ChemoCentryx hereby grants to GSK the exclusive right, exercisable at GSK’s sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds) as set forth below in Section 4.3, as Product Candidates and into Licensed Products under the terms and conditions set forth in this Agreement (each such right to elect, a “Product Option”). Each such Option Compound together with its associated Backup Compounds are collectively referred to as one set of Progressed Compounds, all of which are included within and subject to a single Product Option exercise. For clarity, the exercise by GSK *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. of a Product Option with respect to a given set of Progressed Compounds shall be specific to that particular set of Progressed Compounds only and results in the grant to GSK of the exclusive, worldwide and sublicenseable right and license to Develop and commercialize any Product Candidates or Licensed Products based upon or which incorporate any of such Progressed Compounds. Any additional Collaboration Compounds that are developed subsequently (or in tandem) by ChemoCentryx against the same Collaboration Target (other than the associated Backup Compounds to a given Option Compound) and which progress to become an Option Compound shall be the subject of a separate and distinct Product Option and exercise of the same by GSK.
4.1.2 Upon exercise of a Product Option, GSK shall also have the exclusive worldwide license to develop and commercialize the two (2) Back-up Compounds associated with such Option Compound and selected by the JSC (or Backup Compounds that are otherwise selected by GSK) as set forth in Section 3.6.2 which two (2) Backup Compounds shall be included in the set of Progressed Compounds which are the subject of the same Product Option. Following exercise of its Product Option with respect to an Option Compound, GSK may, in its sole discretion, substitute any one of the two Back-up Compounds for the Option Compound as the selected Product Candidate, or where the Option Compound is successful as a Product Candidate, may in addition, at GSK’s sole discretion, develop and commercialize either or both of its two (2) associated Back-up Compounds, subject to GS...
Product Options. For each Product sold by Diomed beginning on the Effective Date and ending November 15, 2005, Diomed will grant to the LP under the Plan an option (a "Product Option") to purchase five (5) shares of Common Stock of Diomed up to an aggregate maximum of 45,000 shares (which number is inclusive of shares subject to options granted under Section 3.5). The Product Options shall be granted as of the end of each calendar quarter in which Product sales were sold (subject to adjustment for returns and uncollected accounts) and shall be fully vested on grant. The Product Options issued hereunder shall be subject to the same terms as the Initial Options issued under Section 3.5 except that the exercise price of each quarterly grant shall be based on fair market value of Diomed common stock at the time of grant as determined at the sole discretion of the Board of Director and consistent with other Employee options (if any) granted during the quarter.
Product Options. A. Provide products that comply with the Contract Documents, are undamaged, and are new at the time of installation.
1. Provide products complete with accessories, trim, finish, and other devices and components needed for a complete installation and the intended use and effect.
B. Select products to comply with all of the following that are applicable:
1. Where only a single product or manufacturer is named, provide the item indicated. No substitutions will be permitted.
2. Where two or more products or manufacturers are named, provide one of the items indicated. No substitutions will be permitted.
3. Where products or manufacturers are specified by name, accompanied by the term "available products" or "available manufacturers," provide one of the named items or comply with provisions for "comparable product" to obtain approval for use of an unnamed product or manufacturer.
4. Where a single product is named as the "basisofdesign" and no other manufacturers are named, provide the named product or comply with provisions for "comparable product submittal" to obtain approval for use of a product of another manufacturer.
5. Where a product is described with required characteristics, provide a product that complies with those characteristics.
Product Options. With effect from the Effective Date, Autolus hereby grants to BioNTech, on an Option Product-by-Option Product basis, the exclusive option to obtain the exclusive right to co-fund certain development costs in respect of the relevant Option Product in return for a [***] profit sharing arrangement, and to obtain the exclusive option to co-promote and co-commercialize the Option Product, in each case, for all oncology Indications and subject to and as further set out in this Article 4 and Schedule 4.4
Product Options. Information on Drawings and in Specifications establishes requirements for systems' aesthetic effects and performance characteristics. Aesthetic effects are indicated by dimensions, arrangements, alignment, and profiles of components and assemblies as they relate to sightlines, to one another, and to adjoining construction. Performance characteristics are indicated by criteria subject to verification by one or more methods including preconstruction testing, field testing, and in-service performance.
1. Do not revise intended aesthetic effects, as judged solely by Architect, except with Architect's approval. If revisions are proposed, submit comprehensive explanatory data to Architect for review.
Product Options. 22 4.2 Provision of Data ............................................................................................................ 22 4.3
Product Options. Where Specifications indicate that sizes, profiles, and dimensional requirements on Drawings are based on a specific product or system, provide the specified product or system, or approved equal. Comply with provisions in Part 2 "Product Substitutions" Article for consideration of an unnamed product or system.
Product Options. A. Products specified by reference standards or by description only: Any product meeting those standards or description.
B. Products specified by naming one or more manufacturers: Products of manufacturers named and meeting specifications, no options or substitutions allowed.
C. Products specified by naming one or more manufacturers with a provision for substitutions: Submit a request for substitution for any manufacturer not named.
D. For similar components, provide interchangeable components of the same manufacturer.
Product Options. For each EVLT Laser (as defined in the Purchase Agreement) sold by Diomed beginning on the Effective Date and ending November 15, 2005, Diomed will grant to the LLC under the Plan an option (a "Product Option") to purchase twenty five (25) shares of Common Stock of Diomed up to an aggregate maximum of 180,000 shares (which number is inclusive of shares subject to options granted under the 2001 Agreement). For purposes of the foregoing, EVLT Lasers shall be considered "sold" on the date when Diomed has received payment in full for such EVLT Lasers. The Product Options shall be granted as of the end of each calendar quarter in which EVLT Lasers were sold (subject to adjustment for returns and uncollected accounts) and shall be fully vested on grant. The Product Options issued hereunder shall be subject to the same terms as the Product Options issued under Section 3.6 of the 2001 Agreement.
